FDA must publish when drug patents expire—ending secrecy that delays cheaper alternatives
S. 4332 — Medication Competition Act · Filed by Maggie Hassan (D-NH) · 1 cosponsor · Introduced Apr 16, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the FDA to publicly disclose when biological drug patents and exclusivity periods expire, and to do so within 30 days of licensure for new drugs or within 2 years for older drugs already on the market. By making these expiration dates transparent and predictable, the bill aims to help generic and biosimilar manufacturers know when they can legally enter the market, reducing delays and uncertainty that currently protect brand-name biologics from competition.
Why we flagged it
The bill's core mechanism is a transparency mandate: requiring the FDA to publish exclusivity expiration dates for biological products on a fixed timeline. This is a procedural reform designed to accelerate generic and biosimilar market entry by eliminating information delays that currently favor brand-name manufacturers.
What the text implies
- Predictable exclusivity expiration dates may accelerate biosimilar development timelines, potentially shortening the effective market exclusivity period for brand-name biologics beyond the statutory term if manufacturers can now plan launches with certainty.
- The 2-year retroactive disclosure requirement for pre-enactment drugs may create a one-time administrative burden on FDA but also a sudden flood of competitive filings once older drug exclusivity dates become public.
The full analysis lists 3 implications of this text.
Who stands to gain
generic and biosimilar manufacturers; pharmacy benefit managers (via lower acquisition costs); health insurers (via lower drug costs)